Long-term follow-up of people who received EDIT-301 for sickle cell or thalassemia
Follows people with sickle cell disease or beta-thalassemia who received EDIT-301 over time.
Plain-language title generated from the registry record
Registry title: A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
Key facts
- Where
- Ottawa and Toronto, CanadaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 50 years old?
Source: NCT06363760, who can take part
Where in Canada
- Ottawa Hospital Research InstituteOttawa, CanadaNo longer taking part
- Princess Margaret Cancer Centre - University Health NetworkToronto, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Editas Medicine, Inc.
- Trial code
- NCT06363760
- Record updated
- 2 April 2025
- Original description
The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.Read full original descriptionShow less
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.
Inclusion: Participant must have received an EDIT-301 infusion as part of a clinical study; Participant or legal representative/guardian (if applicable) must sign and date the informed consent form (ICF) or assent, if applicable for this long-term follow-up study.
Exclusion: Participant is still actively enrolled in an EDIT-301 treatment study and has not yet met eligibility for long term follow-up in this study.